A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF6467 After Single and Repeated Ascending Doses by Intranasal Route in Healthy Adult Subjects
Latest Information Update: 10 Oct 2025
At a glance
- Drugs CHF 6467 (Primary)
- Indications Foot disorders; Wounds
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chiesi Farmaceutici
Most Recent Events
- 23 Sep 2025 Status changed from not yet recruiting to recruiting.
- 17 Sep 2025 New trial record